Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BRISBANE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
-
Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts Anticipated throughout 2022 and 2023 Operating...
-
BRISBANE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
-
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
-
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month StudyRapid Improvement in Clinical...
-
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
-
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
-
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023...
-
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...
-
BRISBANE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...